Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
169 Leser
Artikel bewerten:
(1)

Sword Health Acquires Surgery Hero to Accelerate Global Growth and Expand its Presence in the UK

Finanznachrichten News

As part of this acquisition, Sword Health will collaborate with 18 NHS trusts serving 10 million people to implement its AI Care model, enhancing care delivery and management while significantly reducing costs

LONDON and NEW YORK, Jan. 24, 2025, a UK-based innovator in prehabilitation digital health. This acquisition bolsters Sword's investment in the UK, where the National Health Service (NHS) faces the challenge of long musculoskeletal care waitlists and high healthcare costs. It also underscores the company's commitment to improving patient outcomes and expanding its impact while expanding their global footprint.

Surgery Hero's expertise in prehabilitation aligns seamlessly with Sword's platform, enabling a more comprehensive approach to care. This collaboration supports faster, smoother recoveries while alleviating pressure on a healthcare system struggling to meet growing patient needs. Surgery Hero's product will remain part of Sword Health's offering and its team will be integrated into Sword.

"Acquiring Surgery Hero is another key step in our mission of freeing the world from pain," said Virgilio ("V") Bento, founder and CEO of Sword Health. "The UK faces a mounting pain crisis, exacerbated by limited access to timely, high-quality care. Sword's AI Care platform removes barriers such as long wait times and travel constraints, providing immediate access and scale to care and ensuring patients receive the support they need when and where they need it."

In the UK, more than one million people1 are currently waiting to access musculoskeletal treatments, leading to delayed care and prolonged recoveries. Sword Health's innovative solutions address these challenges by expanding access, reducing costs, improving clinical outcomes, and enhancing patient satisfaction.

"Joining forces with Sword Health allows us to expand the scope of our services and deliver better care to patients," said Surgery Hero's CEO, Dr Matthew Beatty. "Together, we are committed to providing patients with the resources they need to improve their health before surgery and optimise their recovery."

This acquisition marks a significant milestone in Sword's mission to transform healthcare through AI. By integrating prehabilitation services, Sword is positioned to offer comprehensive support in the UK, from pre-surgery through recovery, expanding its already large global footprint and ensuring high-quality care reaches all members in need.

About Sword Health

As a global leader in AI Care, Sword Health makes world-class care available anytime, anywhere, by combining human clinicians and AI. Starting with physical pain, then pelvic health, and now a full platform of solutions, Sword is available through more than 25,000 employers, health plans, and public sector organizations, saving those clients an average of $3 in healthcare costs for every $1 invested in Sword. To date, the company has saved its clients more than $650 million in unnecessary healthcare costs. With a mission to free two billion people from pain, the company has raised more than $300 million from leading venture firms, including Khosla Ventures and General Catalyst. It was most recently valued at $3 billion and won Fast Company's World Changing Ideas Award in the health services category. Learn more at www.swordhealth.com.

About Surgery Hero

Surgery Hero is a digital health company dedicated to enhancing patient outcomes through innovative digital solutions. Their flagship product, Surgery Hero, provides comprehensive support for patients undergoing surgery, helping them to prepare, recover, and thrive in their surgical journeys. Learn more at www.surgeryhero.com.

1NHS England

Media contact: Press@swordhealth.com


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.